+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Regenerative Medicine Market - Global Outlook and Forecast 2021-2026

  • ID: 5336112
  • Report
  • June 2021
  • Region: Global
  • Arizton
UP TO OFF
until Sep 30th 2021

FEATURED COMPANIES

  • Amgen
  • Bristol Myers Squibb
  • Gilead Sciences
  • Medipost
  • Nuvasive
  • S-BIOMEDIC
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

In-depth Analysis and Data-driven Insights on the Impact of COVID-19 Included in this Global Regenerative Medicine Market Report



The regenerative medicine market size to grow at a CAGR of around 34% during the period 2020-2026.

Increased R&D investments by pharmaceutical companies will drive the demand for regenerative medicines. Europe plays a significant role in supporting the development and authorization of these products for several genetic and rare disorders. Increased funding via several venture capitalists and governments, and private institutions contribute significantly to the global regenerative medicine market growth. The increased prevalence of diseases such as cardiovascular diseases and diabetes can drive cell and gene therapy and tissue-engineered products. With the rise in thermal burns, occupational burn accidents, and chronic wounds, regenerative medicine products will experience steady growth. Novartis and Gilead Sciences are the key companies offering various therapies to treat cancer, genetic, and rare disorders.

The following factors are likely to contribute to the growth of the regenerative medicine market during the forecast period:
  • Increase in the Patient Pool with Acute, Chronic, and Genetic Disorders
  • Strong Pipeline Portfolio of Regenerative Medicine Companies
  • Implementation of Advanced tissue-engineering Therapies Technology
  • Faster Regulatory approvals
The report considers the present scenario of the regenerative medicine market and its market dynamics for 2019-2026. It covers a detailed overview of several market growth enablers, restraints, and trends. The study covers both the demand and supply sides of the market. It also profiles and analyzes leading companies and several other prominent companies operating in the market.

REGENERATIVE MEDICINE MARKET SEGMENTATION

The regenerative medicine market research report includes a detailed segmentation by application, products, end-users, geography. Oncology constitutes the largest portion of the global regenerative medicine market share. The development of curative therapies by CAR-T and cell and gene therapies is widely popularized in the oncology therapeutic area. The increasing global prevalence rates and the increasing rates of different types of life-threatening cancers are the most important key factors that drive the oncology segment.

Consistent innovations in gene therapies due to the increased number of clinical trials and pipeline products are driving the growth prospects. Hence, the increased inflow of funding for the development of gene therapy is one of the driving factors for the sector growth Cell therapy is the major revenue contributor. The increasing prevalence of diabetes and foot ulcers is the primary factor contributing to the growth of tissue-engineered products. The tissue-engineered product segment to grow at a CAGR of 8% by 2026.

Hospitals are likely to remain a dominant revenue contributor to the global regenerative medicine market. Around 50% of therapeutic surgeries performed in the US annually, including cardiovascular and musculoskeletal, occur in hospitals. Cancer care centers are likely to witness an incremental growth of approx. USD 10 billion by 2026. As cancer is the second leading cause of death across the globe, which is responsible for approx. 10 million deaths annually, the scope of cancer centers is growing. Key vendors are focusing more on cancer care centers than hospitals to promote their products. As the cancer centers are being covered under reimbursement schemes, the growth of these facilities is likely to increase during the forecast period.

Segmentation by Application
  • Oncology
  • Genetic Disorders
  • Dermatology
  • Musculoskeletal
  • Others
Segmentation by Product
  • Gene Therapies
  • Cell Therapies
  • Tissue-Engineered Therapies
Segmentation by End-Users
  • Hospitals
  • Cancer Care Centers
  • Wound Care Centers
  • ASCs
  • Others
INSIGHTS BY GEOGRAPHY

In North America, the acceptance of regenerative medicine is relatively higher than in other developed countries. North America to accounts for the largest market share of the global regenerative medicine market. The growth can be primarily attributed to the increasing population with different types of cancers such as non-Hodgkin lymphoma, Hodgkin lymphoma, melanoma of the skin, and leukaemia in the North American region. Furthermore, North America consists of the highest number of regenerative medicine companies, which is adding to the market growth in the region. Europe has highly developed manufacturing facilities, which is driving the market growth in the European region. Most vendors in Europe depend on external sources for expansion and R&D activities.

Segmentation by Geography
  • North America
  • US
  • Canada
  • Europe
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • APAC
  • Japan
  • China
  • Australia
  • South Korea
  • India
  • Latin America
  • Brazil
  • Mexico
  • Middle East & Africa
  • Turkey
  • Saudi Arabia
  • South Africa
  • UAE
COMPETITIVE LANDSCAPE

Amgen, Bristol Myers Squibb, Dendreon, F. Hoffmann-La Roche, Gilead Sciences, Novartis, Osiris, Organogenesis, and Vericel are the key vendors in the global regenerative medicine market. Global key players dominate the market shares due to wide distribution networks, innovative product launches, and broad product offerings. Companies are focusing on product innovations and strengthening their distribution channel to expand market presence globally. The market has developed innovative therapies in the field. For instance, Bristol Myers Squibb received approval from the US FDA for its product - Lisocel - to treat relapsed/refractory diffuse large-B cell lymphoma (DLBCL) in February 2021. Small players are collaborating with prominent players to gain a competitive advantage in the market.

Key Vendors
  • Novartis
  • Gilead Sciences
  • Amgen
  • Organogenesis
  • Bristol Myers Squibb
  • Vericle
  • Osiris Therapeutics
Other Prominent Vendors
  • Anges
  • Orchard Therapeutics
  • Orthofix
  • Integra Life Science
  • MiMedx
  • bluebird bio
  • Mesoblast
  • Avita Medical
  • Takeda Pharmaceuticals
  • Medipost
  • TissueTech
  • Misonix
  • J-TEC
  • Stempeutics
  • CO.DON
  • GC Pharma
  • Orthocell
  • Tego Science
  • Nipro
  • S-BIOMEDIC
  • APAC Biotech
  • Bio Solution
  • Chiesi Farmaceutici
  • Collplant
  • Corestem
  • Human Stem Cell Institute
  • JCR Pharmaceuticals
  • JW CreaGene
  • Nuvasive
  • Sibiono GeneTech
  • Shanghai Sunway Biotech
  • Terumo
KEY QUESTIONS ANSWERED:
1. How big is the regenerative medicine market?
2. What are the critical applications of regenerative medicine products?
3. Who are the key players in the regenerative medicine market?
4. Which segment accounted for the largest regenerative medicine market share?
5. Which region holds the largest share in the global regenerative medicine market?
6. How has the COVID-19 pandemic affected the regenerative medicine industry?
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Amgen
  • Bristol Myers Squibb
  • Gilead Sciences
  • Medipost
  • Nuvasive
  • S-BIOMEDIC
1 Research Methodology

2 Research Objectives

3 Research Process

4 Scope & Coverage
4.1 Market Definition
4.1.1 Inclusions
4.1.2 Exclusions
4.2 Base Year
4.3 Scope of The Study
4.3.1 Market Segmentation By Application
4.3.2 Market Segmentation By Product
4.3.3 Market Segmentation By End-users
4.3.4 Market Segmentation by Geography

5 Report Assumptions & Caveats
5.1 Key Caveats
5.2 Currency Conversion
5.3 Market Derivation

6 Market at a Glance

7 Introduction
7.1 Overview

8 Market Opportunities & Trends
8.1 Latest Advances In Tissue-Engineering Therapies
8.2 Robust Product Pipeline Of Regenerative Medicine Companies
8.3 Strategic Acquisitions By Regenerative Medicine Companies

9 Market Growth Enablers
9.1 Increase In Acute, Chronic, & Genetic Disorders
9.2 Increasing Demand For Car T-Cell Therapies
9.3 Faster Regulatory Approvals & Special Designations Of Rm Products

10 Market Restraints
10.1 Manufacturing, Operational, & Ethical Challenges
10.2 High Cost of Regenerative Therapies
10.3 Outbreak of The COVID-19 Pandemic

11 Market Landscape
11.1 Market Overview
11.2 Market Size & Forecast
11.3 Five Forces Analysis
11.3.1 Threat of New Entrants
11.3.2 Bargaining Power of Suppliers
11.3.3 Bargaining Power of Buyers
11.3.4 Threat of Substitutes
11.3.5 Competitive Rivalry

12 Application
12.1 Market Snapshot & Growth Engine
12.2 Market Overview
12.3 Dermatology
12.3.1 Market Overview
12.3.2 Market Size & Forecast
12.4 Musculoskeletal
12.4.1 Market Overview
12.4.2 Market Size & Forecast
12.5 Oncology
12.5.1 Market Overview
12.5.2 Market Size & Forecast
12.6 Genetic Disorders
12.6.1 Market Overview
12.6.2 Market Size & Forecast
12.7 Other Applications
12.7.1 Market Overview
12.7.2 Market Size & Forecast

13 Product
13.1 Market Snapshot & Growth Engine
13.2 Market Overview
13.3 Gene Therapy
13.3.1 Market Overview
13.3.2 Market Size & Forecast
13.4 Cell Therapy
13.4.1 Market Overview
13.4.2 Market Size & Forecast
13.5 Tissue-Engineering
13.5.1 Market Overview
13.5.2 Market Size & Forecast

14 End-Users
14.1 Market Snapshot & Growth Engine
14.2 Market Overview
14.3 Hospitals
14.3.1 Market Overview
14.3.2 Market Size & Forecast
14.4 Cancer Care Centers
14.4.1 Market Overview
14.4.2 Market Size & Forecast
14.5 Wound Care Centers
14.5.1 Market Overview
14.5.2 Market Size & Forecast
14.6 Ambulatory Surgical Centers
14.6.1 Market Overview
14.6.2 Market Size & Forecast
14.7 Others
14.7.1 Market Overview
14.7.2 Market Size & Forecast

15 Geography
15.1 Market Snapshot & Growth Engine
15.2 Geographic Overview

16 North America
16.1 Market Overview
16.2 Market Size & Forecast
16.3 Key Countries
16.3.1 US: Market Size & Forecast
16.3.2 Canada: Market Size & Forecast

17 Europe
17.1 Market Overview
17.2 Market Size & Forecast
17.3 Key Countries
17.3.1 Germany: Market Size & Forecast
17.3.2 France: Market Size & Forecast
17.3.3 UK: Market Size & Forecast
17.3.4 Italy: Market Size & Forecast
17.3.5 Spain: Market Size & Forecast

18 APAC
18.1 Market Overview
18.2 Market Size & Forecast
18.3 Key Countries
18.3.1 Japan: Market Size & Forecast
18.3.2 China: Market Size & Forecast
18.3.3 Australia: Market Size & Forecast
18.3.4 South Korea: Market Size & Forecast
18.3.5 India: Market Size & Forecast

19 Latin America
19.1 Market Overview
19.2 Market Size & Forecast
19.3 Key Countries
19.3.1 Brazil: Market Size & Forecast
19.3.2 Mexico: Market Size & Forecast

20 Middle East & Africa
20.1 Market Overview
20.2 Market Size & Forecast
20.3 Key Countries
20.3.1 Turkey: Market Size & Forecast
20.3.2 Saudi Arabia: Market Size & Forecast
20.3.3 South Africa: Market Size & Forecast
20.3.4 UAE: Market Size & Forecast

21 Competitive Landscape
21.1 Competition Overview
21.2 Market Share Analysis
21.2.1 Novartis
21.2.2 Gilead Sciences
21.2.3 Amgen
21.2.4 Dendreon
21.2.5 Organogenesis
21.2.6 Bristol-Myers Squibb
21.2.7 Vericel
21.2.8 Osiris Therapeutics
21.2.9 F. Hoffmann-La Roche

22 Key Company Profiles
22.1 Novartis
22.1.1 Business Overview
22.1.2 Product Offerings
22.1.3 Key Strategies
22.1.4 Key Strengths
22.1.5 Key Opportunities
22.2 Gilead Sciences
22.2.1 Business Overview
22.2.2 Product Offerings
22.2.3 Key Strategies
22.2.4 Key Strengths
22.2.5 Key Opportunities
22.3 Amgen
22.3.1 Business Overview
22.3.2 Product Offerings
22.3.3 Key Strategies
22.3.4 Key Strengths
22.3.5 Key Opportunities
22.4 Organogenesis
22.4.1 Business Overview
22.4.2 Product Offerings
22.4.3 Key Strategies
22.4.4 Key Strengths
22.4.5 Key Opportunities
22.5 Bristol-Myers Squibb
22.5.1 Business Overview
22.5.2 Product Offerings
22.5.3 Key Strategies
22.5.4 Key Strengths
22.5.5 Key Opportunities
22.6 Vericel
22.6.1 Business Overview
22.6.2 Product Offerings
22.6.3 Key Strategies
22.6.4 Key Strengths
22.6.5 Key Opportunities
22.7 Osiris Therapeutics
22.7.1 Business Overview
22.7.2 Product Offerings
22.7.3 Key Strategies
22.7.4 Key Strengths
22.7.5 Key Opportunities

23 Other Prominent Vendors
23.1 ANGES
23.1.1 Business Overview
23.1.2 Product Offerings
23.2 APAC Biotech
23.2.1 Business Overview
23.2.2 Product Offerings
23.3 Avita Medical
23.3.1 Business Overview
23.3.2 Product Offerings
23.4 Bio Solution
23.4.1 Business Overview
23.4.2 Product Offerings
23.5 bluebird bio
23.5.1 Business Overview
23.5.2 Product Offerings
23.6 Chiesi Farmaceutici
23.6.1 Business Overview
23.6.2 Product Offerings
23.7 CO.DON
23.7.1 Business Overview
23.7.2 Product Offerings
23.8 Collplant
23.8.1 Business Overview
23.8.2 Product Offerings
23.9 Corestem
23.9.1 Business Overview
23.10 GC Pharma
23.10.1 Business Overview
23.10.2 Product Offerings
23.11 Human Stem Cell Institute
23.11.1 Business Overview
23.11.2 Product Offerings
23.12 Integra Life Sciences
23.12.1 Business Overview
23.12.2 Product Offerings
23.13 JCR Pharmaceuticals
23.13.1 Business Overview
23.13.2 Product Offerings
23.14 J-TEC
23.14.1 Business Overview
23.14.2 Product Offerings
23.15 JW CreaGene
23.15.1 Business Overview
23.15.2 Product Offerings
23.16 MEDIPOST
23.16.1 Business Overview
23.16.2 Product Offerings
23.17 MiMedx
23.17.1 Business Overview
23.17.2 Product Offerings
23.18 Misonix
23.18.1 Business Overview
23.18.2 Product Offerings
23.19 Mesoblast
23.19.1 Business Overview
23.19.2 Product Offerings
23.20 Nipro
23.20.1 Business Overview
23.20.2 Product Offerings
23.21 Nuvasive
23.21.1 Business Overview
23.21.2 Product Offerings
23.22 Orchard Therapeutics
23.22.1 Business Overview
23.22.2 Product Offerings
23.23 Orthifix
23.23.1 Business Overview
23.23.2 Product Offerings
23.24 Orthocell
23.24.1 Business Overview
23.24.2 Product Offerings
23.25 S.BIOMEDICS
23.25.1 Business Overview
23.25.2 Product Offerings
23.26 Sibiono GeneTech
23.26.1 Business Overview
23.26.2 Product Offerings
23.27 Shanghai Sunway Biotech
23.27.1 Business Overview
23.27.2 Product Offerings
23.28 Stempeutics
23.28.1 Business Overview
23.28.2 Product Offerings
23.29 Takeda Pharmaceuticals
23.29.1 Business Overview
23.29.2 Product Offerings
23.30 Tego Science
23.30.1 Business Overview
23.30.2 Product Offerings
23.31 Terumo
23.31.1 Business Overview
23.31.2 Product Offerings
23.32 Tissuetech
23.32.1 Business Overview
23.32.2 Product Offerings

24 Report Summary
24.1 Key Takeaways
24.2 Strategic Recommendations

25 Quantitative Summary
25.1 Market By Geography
25.2 Market By Application
25.3 Market By Product
25.4 Market By End-User

26 Appendix
26.1 Abbreviations
Note: Product cover images may vary from those shown

A selection of companies mentioned in this report includes:

  • Novartis
  • Gilead Sciences
  • Amgen
  • Organogenesis
  • Bristol Myers Squibb
  • Vericle
  • Osiris Therapeutics
  • Anges
  • Orchard Therapeutics
  • Orthofix
  • Integra Life Science
  • MiMedx
  • bluebird bio
  • Mesoblast
  • Avita Medical
  • Takeda Pharmaceuticals
  • Medipost
  • TissueTech
  • Misonix
  • J-TEC
  • Stempeutics
  • CO.DON
  • GC Pharma
  • Orthocell
  • Tego Science
  • Nipro
  • S-BIOMEDIC
  • APAC Biotech
  • Bio Solution
  • Chiesi Farmaceutici
  • Collplant
  • Corestem
  • Human Stem Cell Institute
  • JCR Pharmaceuticals
  • JW CreaGene
  • Nuvasive
  • Sibiono GeneTech
  • Shanghai Sunway Biotech
  • Terumo
Note: Product cover images may vary from those shown

Our research comprises a mix of primary and secondary research. The secondary research sources that are typically referred to include, but are not limited to, company websites, annual reports, financial reports, company pipeline charts, broker reports, investor presentations and SEC filings, journals and conferences, internal proprietary databases, news articles, press releases, and webcasts specific to the companies operating in any given market.

Primary research involves email interactions with the industry participants across major geographies. The participants who typically take part in such a process include, but are not limited to, CEOs, VPs, business development managers, market intelligence managers, and national sales managers. We primarily rely on internal research work and internal databases that we have populated over the years. We cross-verify our secondary research findings with the primary respondents participating in the study.



 

Loading
LOADING...

Adroll
adroll